Seven reasons the beleaguered biotech sector is now a ‘buy’ By: MarketWatch June 17, 2022 at 10:17 AM EDT Investors ought to take advantage of low prices for a long-term view. Read More >> Related Stocks: Alnylam Pharmaceuticals Baxter International Biogen Idec Boston Scientific Bristol-Myers Squibb Cardinal Health Gilead Sciences Johnson & Johnson Karuna Therapeutics Inc Medtronic Mirati Therapeutics Natera Inc Roche Holding AG Basel American Depositary Shares S&P Biotech SPDR Stryker Corp Turning Point Therapeutics Inc Vertex Pharmaceuticals
